J Korean Ophthalmol Soc.  2013 Sep;54(9):1359-1364.

Long-Term Effect of Intravitreal Ranibizumab Injection on Choroidal Neovascularization in Age-Related Macular Degeneration

• Jang HJ
• Song SJ
• Bae JH

Abstract

PURPOSE
To evaluate long-term efficacy and safety of intravitreal ranibizumab on choroidal neovascularization (CNV) in age-related macular degeneration (AMD) in Korean patients over a 2-year period.
METHODS
Twenty-three eyes of 23 patients who underwent intravitreal ranibizumab injection for secondary CNV in AMD were followed up more than 2 years, and their records were retrospectively investigated. The best corrected visual acuity (BCVA), central macular thickness (CRT) were compared at baseline and at 6, 12, 18 and 24 months after injection.
RESULTS
The mean BCVA (log MAR) was 0.58 +/- 0.36, 0.54 +/- 0.49, 0.59 +/- 0.49, 0.64 +/- 0.51, and 0.61 +/- 0.51 at baseline, 6, 12, 18 and 24 months, respectively (p = 0.332, p = 1.000, p = 0.670, p = 0.697). The mean CRT was 283.75 +/- 61.41 microm, 239.93 +/- 53.12 microm, 244.89 +/- 47.44 microm, 246.36 +/- 55.78, and 244.70 +/- 54.86 at baseline, 6, 12, 18 and 24 months, respectively (p = 0.009, p = 0.036, p = 0.01, p = 0.015). The mean number of injection was 5.96 +/- 2.93 over a 2-year period.
CONCLUSIONS
In Korean patients who underwent intravitreal ranibizumab injection for secondary CNV in AMD, long-term efficacy in diminishing CRT was evident. However, long-term efficacy in increasing visual acuity was not observed.

Keyword

Age-related macular degeneration; Choroidal neovascularization; Ranibizumab

MeSH Terms

Antibodies, Monoclonal, Humanized
Choroid
Choroidal Neovascularization
Eye
Humans
Macular Degeneration
Retrospective Studies
Visual Acuity
Ranibizumab
Antibodies, Monoclonal, Humanized

Reference

References

1. Friedman DS, O'Colmain BJ, Muñoz B. . Prevalence of age-re-lated macular degeneration in the United States. Arch Ophthalmol. 2004; 122:564–72.

2. Augood C, Fletcher A, Bentham G. . Methods for a pop-ulation-based study of the prevalence of and risk factors for age-re-lated maculopathy and macular degeneration in elderly European populations: the EUREYE study. Ophthalmic Epidemiol. 2004; 11:117–29.

3. Resnikoff S, Pascolini D, Etya'ale D. . Global data on visual impairment in the year 2002. Bull World Health Organ. 2004; 82:844–51.

4. Au Eong KG. Age-related macular degeneration: an emerging challenge for eye care and public health professionals in the Asia Pacific region. Ann Acad Med Singapore. 2006; 35:133–5.

5. Kliffen M, Sharma HS, Mooy CM. . Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol. 1997; 81:154–62.

6. Otani A, Takagi H, Oh H. . Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res. 2002; 64:162–9.

7. Rakic JM, Lambert V, Devy L. . Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003; 44:3186–93.

8. Rosenfeld PJ, Brown DM, Heier JS. . Ranibizumab for neo-vascular age-related macular degeneration. N Engl J Med. 2006; 355:1419–31.

9. Brown DM, Kaiser PK, Michels M. . Ranibizumab versus ver-teporfin for neovascular age-related macular degeneration. N Engl J Med. 2006; 355:1432–44.

10. Kwon OW, Lee FL, Chung H. . EXTEND III: Efficacy and safety of ranibizumab in South Korean and Taiwanese patients with subfoveal CNV secondary to AMD. Graefes Arch Clin Exp Ophthalmol. 2012; 250:1467–76.

11. Fung AE, Lalwani GA, Rosenfeld PJ. . An optical coherence tomography-guided, variable dosing regimen with intravitreal ra-nibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007; 143:566–83.

12. Kang SB, Cho WK, Roh YJ. The efficacy of ranibizumab for cho-roidal neovascularization in age-related macular degeneration. J Korean Ophthalmol Soc. 2009; 50:725–30.

13. Ferrara N, Damico L, Shams N. . Development of ranibizu-mab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006; 26:859–70.

14. Gaudreault J, Fei D, Rusit J. . Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005; 46:726–33.

15. Tano Y, Ohji M; EXTEND-I Study Group. Long-term efficacy and safety of ranibizumab administered pro re nata in Japanese patients with neovascular age-related macular degeneration in the EXTEND-I study. Acta Ophthalmol. 2011; 89:208–17.

16. Holz FG, Amoaku W, Donate J. . Safety and efficacy of a flexi-ble dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011; 118:663–71.

17. Rosa RH Jr, Davis JL, Eifrig CW. Clinicopathologic reports, case reports, and small case series: clinicopathologic correlation of idio-pathic polypoidal choroidal vasculopathy. Arch Ophthalmol. 2002; 120:502–8.

18. Gomi F, Sawa M, Sakaguchi H. . Efficacy of intravitreal bev-acizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol. 2008; 92:70–3.